The negative trailing P/E is not meaningful for relative valuation, so the EV/EBITDA of 11.31 and forward EV/EBITDA of 13.14 are the more useful anchors, and the forward multiple sitting above the trailing figure suggests the market expects EBITDA to compress further. The P/B of 0.55 indicates a substantial discount to book equity, consistent with ROE of -9.0% and ongoing equity erosion. Relative to peers such as LYB at 7.55x EV/EBITDA and EMN at 8.25x, HUN's multiple appears elevated, which may indicate the market is capitalizing a cyclical trough in EBITDA rather than a durable earnings base, warranting further investigation of EBITDA normalization.

The erosion from the mid-2024 gross margin level suggests weaker price-over-cost in the MDI chain or reduced volume absorption rather than a one-time item. Operating margin has recovered to a positive 2.3% in the latest quarter after running negative for much of the period, but net margin remains negative, implying interest and other non-operating charges continue to consume operating profit. Versus peers, HUN's 13.8% gross margin is competitive, yet its trailing net margin of -4.8% lags EMN's 5.4%, pointing to a burden from financing costs and overhead rather than production economics alone.

ROIC oscillating around zero across the period suggests the capital base is not generating returns above its cost of capital, a central concern for a capital-intensive chemical producer. Trailing ROE of -9.0% reflects losses eroding equity, and the decline from roughly $3.1B to $2.7B over two years means the denominator is shrinking while earnings remain negative. The gap relative to EMN appears structural rather than purely cyclical, likely reflecting differences in product mix and cost position. Investors should monitor whether margin recovery translates into sustained positive ROIC above roughly 8%, a threshold typically needed for value creation in this sector.

The rise in debt-to-equity reflects a combination of relatively stable debt and shrinking equity, meaning deleveraging has not kept pace with losses. Interest coverage of 2.13 in the latest quarter is recovering from negative readings earlier in the period, but a level near 2x leaves limited room for further EBITDA decline before debt service becomes strained. The debt-to-EBITDA ratio of 21.03 signals that earnings, rather than the debt stock alone, are the binding constraint. The provided data does not disclose maturity profile or covenant terms, so conclusions on near-term refinancing risk warrant further investigation.

The gap in net margin and ROE relative to Eastman Chemical appears structural, plausibly tied to HUN's heavier exposure to commodity-linked MDI chains, whereas EMN's specialty mix supports stronger returns through the cycle. Against the broader group, HUN's gross margin is competitive, so the deficit sits in overhead, interest, and non-operating charges rather than core production economics. The depressed P/B of 0.55 versus LYB at 1.92 and EMN at 1.23 indicates the market is assigning limited value to book equity given negative returns. Whether the gap is temporary depends on a sustained recovery in MDI utilization, which the provided data does not confirm.